Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV Open Label, Multicentre, Investigational Study of the Therapeutic Options for Subjects Discontinuing Efalizumab Therapy and Experiencing Inflammatory Disease Recurrence

NCT01079988 is registered in ClinicalTrials.gov with Merck KGaA, Darmstadt, Germany as lead sponsor.

NCT NCT01079988
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01079988 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV Open Label, Multicentre, Investigational Study of the Therapeutic Options for Subjects Discontinuing Efalizumab Therapy and Experiencing Inflammatory Disease Recurrence
Lead sponsor
Merck KGaA, Darmstadt, Germany
Phase
Phase 4
Overall status
Completed
Start date
February 29, 2004
Completion date
April 30, 2005
Enrollment
41 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis